Dose-expansion group:Gene-modified tumor infiltrating lymphocytes

Phase I clinical study on the tolerance and safety of ScTIL (enhanced receptor and chimeric antigen receptor modified circulating tumor infiltrating lymphocytes, ECAR-T) in patients with CD19 positive recurrent or refractory non-Hodgkin lymphoma

Phase I clinical study on the safety and effectiveness of ECAR-T (Enhanced receptor and chimeric antigen receptor - modified PD1-positive T cell) in the treatment of CD19-positive relapsed or refractory non-Hodgkin's lymphoma